Corporate ProfileTocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.
NASDAQ GS TOCA (Common Stock)
$10.92 + 0.42
02/22/19 4:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
Tocagen to Report Fourth Quarter and Full Year Financial Results on Wednesday, February 27 and Present at Upcoming SVB Leerink Global Healthcare Conference02/20/19
Tocagen Announces Pricing of Public Offering of Common Stock12/12/18
Tocagen Announces Proposed Public Offering of Common Stock12/11/18
Friday, March 1, 20199:30 a.m. ET
8th Annual SVB Leerink Global Healthcare Conference